MINK THERAPEUTICS INC

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

30 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

20 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Reports Third Quarter 2023 Results

09 Nov 2023 06:00:01 By Nasdaq GlobeNewswire

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

27 Sep 2023 08:05:00 By Nasdaq GlobeNewswire

MiNK Therapeutics to Participate in September Investor Conferences

24 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Reports Second Quarter 2023 Results

10 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

28 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

05 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference

22 May 2023 07:30:00 By Nasdaq GlobeNewswire

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT

18 May 2023 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

11 May 2023 07:00:02 By Nasdaq GlobeNewswire

MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results

27 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting

18 Apr 2023 12:32:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

21 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting

15 Mar 2023 07:45:00 By Nasdaq GlobeNewswire

MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

07 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

16 Feb 2023 08:28:43 By Nasdaq GlobeNewswire